title: Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era.
abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma. The incidence of Epstein-Barr virus (EBV)-positive DLBCL in Asian and Latin American countries ranges from 8 to 10%. The prognosis of patients with EBV-positive DLBCL is controversial. To compare the clinical outcome of EBV-positive and EBV-negative patients with DLBCL in the rituximab era, we analyzed 239 patients with de novo DLBCL diagnosed between January 2007 and December 2011. The presence of EBV in lymphoma cells was detected using EBV-encoded RNA in situ hybridization, and it was found that 18 (6.9%) of 260 patients with diagnosed DLBCL tested positive. Among the 260 cases, 216 cases were treated with rituximab plus chemotherapy, as were 8 EBV-positive DLBCL patients. The median overall survival and progression-free survival times in patients with EBV-positive DLBCL were 8.7 months and 6.8 months, respectively. The median overall survival and progression-free survival could not be determined in EBV-negative DLBCL patients (P = 0.0002, P < 0.0001, respectively). The outcome of patients with EBV-positive DLBCL remains poor, even in the rituximab era.
authors: Department of Hematology-Oncology, School of Medicine, Tokai University, Isehara, Japan.
authors: Ai
authors: A
authors: Sato
authors: Naoya
authors: N
authors: Nakamura
authors: Minoru
authors: M
authors: Kojima
authors: Ken
authors: K
authors: Ohmachi
authors: Joaquim
authors: J
authors: Carreras
authors: Yara Yukie
authors: YY
authors: Kikuti
authors: Hiroki
authors: H
authors: Numata
authors: Daisuke
authors: D
authors: Ohgiya
authors: Kei
authors: K
authors: Tazume
authors: Jun
authors: J
authors: Amaki
authors: Makiko
authors: M
authors: Moriuchi
authors: Mitsuki
authors: M
authors: Miyamoto
authors: Yasuyuki
authors: Y
authors: Aoyama
authors: Hidetsugu
authors: H
authors: Kawai
authors: Akifumi
authors: A
authors: Ichiki
authors: Ryujiro
authors: R
authors: Hara
authors: Hiroshi
authors: H
authors: Kawada
authors: Yoshiaki
authors: Y
authors: Ogawa
authors: Kiyoshi
authors: K
authors: Ando
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000401:mortality; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality / Q000821:virology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D016016:Proportional Hazards Models; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Diffuse large B-cell lymphoma; Epstein-Barr virus (EBV); prognosis